Combination containing sGC stimulators and mineralocorticoid receptor antagonists
AssigneeBayer Pharma Aktiengesellschaft
InventorsPeter Kolkhof, Peter Sandner
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
Claims25
A method for the treatment of cardiovascular disorders, renal disorder, pulmonary disorders, and/or fibrotic disorders, comprising administering a therapeutically effective amount of a combination of an sGC stimulator and a non-steroidal MR antagonist to a human or animal in need thereof, wherein the sGC simulator is (methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyridmidin-5-yl}carbamate) of the formula (X)
- and the non-steroidal MR antagonist is (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (IV)
A kit comprising an sGC stimulator that is (methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyridmidin-5-yl}carbamate) of the formula (X)
- and a non-steroidal MR antagonist that is (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (IV)
- wherein the sGC stimulator and the non-steroidal MR antagonist are in different dose forms.
A medicament comprising an sGC stimulator that is (methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]pyridmidin-5-yl}carbamate) of the formula (X)
- a non-steroidal MR antagonist that is (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (IV)
- and an inert, non-toxic, pharmaceutically suitable auxiliary, wherein the sGC simulator of the formula (X) has a dosage of from about 0.5 to 50 mg od and the non-steroidal MR antagonist of the formula (IV) has a dosage of from about 1 to 100 mg od.
A method for the treatment of diabetic renal failure, non-diabetic renal failure, diabetic retinopathy, and/or non-diabetic retinopathy, comprising administering a therapeutically effective amount of a combination of an sGC stimulator and a non-steroidal MR antagonist to a human or animal in need thereof, wherein the sGC simulator is (methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyridmidin-5-yl}carbamate) of the formula (X)
- and the non-steroidal MR antagonist is (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (IV)
Dependencies are inferred from the claim text.